Grants and Contributions:
Title:
Preclinical development of a combination therapy for the treatment of Hirschsprung disease in newborns
Agreement Number:
1033406
Agreement Value:
$250,000.00
Agreement Date:
Jul 2, 2025 - Mar 27, 2026
Description:
The project advances preclinical development of the first non-surgical treatment for Hirschsprung disease, a rare congenital disorder that causes severe gastrointestinal issues and risk of sepsis in affected newborns.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H3B 1S6
Reference Number:
172-2025-2026-Q2-1033406
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
710310533
Recipient Type:
For-profit organization
Recipient's Legal Name:
NEURENATI THERAPEUTIQUE INC./NEURENATI THERAPEUTICS INC.
Federal Riding Name:
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding Number:
24077
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710